Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma Subtypes
Research presented at the 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR demonstrated favorable results for various types of lymphoma.
Diagnosis & Disease Information
Mega-Dose Decitabine May Improve Conditioning Before Allo-HSCT in AML
Researchers sought to determine whether a larger dose of decitabine prior to allo-HSCT would improve outcomes in patients with AML.
Iomab-B Enables ASCT in AML Patients Typically Not Eligible for Transplant
Iomab-B plus RIC enables ASCT in a population of AML patients who are not typically eligible for transplant, a phase 3 study suggests.
Treatment-Related Changes in Physical Function Affect Post-Transplant Survival in Older Adults with AML
Researchers sought to determine whether changes in physical function during intensive chemotherapy would affect post-transplant survival in older adults with AML.
Orca-T Improves Allo-HSCT Outcomes Compared With Historical Control
Researchers sought to determine whether Orca-T could improve relapse and survival outcomes compared with historical controls for patients receiving allo-HSCT.
Responses Fleeting With CAR-T Reinfusion in Children, AYAs With B-ALL
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
Reducing IV Crystalloid Fluid Administration May Reduce Risk of Respiratory Failure in Haplo-SCT
Researchers sought to determine whether reducing IV crystalloid fluid administration may decrease the risk of respiratory failure in patients receiving haplo-SCT.
Siltuximab Shows Promising Efficacy Against CRS and ICANS
Researchers sought to determine whether siltuximab would be safe and effective for treating CRS and ICANS associated with CAR-T therapy.
Delayed Immune Recovery Predictive of Worse Overall Survival in Adults Following Allo-HCT
Researchers evaluated whether patients who undergo allo-HCT who have a rapid and robust immune recovery have improved clinical outcomes, including OS rates.
Promising Prophylactic Efficacy With RGI-2001 Plus Standard of Care for Acute GVHD
Researchers sought to determine whether adding RGI-2001 to a calcineurin inhibitor and methotrexate or mycophenolate mofetil would help prevent acute GVHD.
- Loading...
Loading...
Next post in Tandem Meetings 2023
Loading... 
Loading...